Innovative Inhaled Antipsychotic Formulation Adasuve Provides Quick and Effective Treatment
Experts attending the European Psychiatry Association Congress in Vienna say that Adasuve has made an impact in the treatment of agitation in patients suffering from schizophrenia or biopolar I disorder.
Adasuve, an oral inhalation product that combines the patented Staccato system with the antipsychotic loxapine, was approved by EMA in February 2013. The formulation has since benefitted 5000 patients in Europe, according to Rudolf Widmann, CEO of AOP Orphan, speaking at the European Psychiatry Association Congress in Vienna. Experts at the event also confirmed that Adasuve has made an impact in the treatment of agitation in patients suffering from schizophrenia or biopolar I disorder.
In the Staccato system, loxapine is evaporated to produce an aerosol that is absorbed by the lungs. The drug is transported into the systemic circulation through the lungs, and patients notice a decrease in agitation within 10 minutes.
Available in doses of 9.1 mg, Adasuve is indicated to control cases of mild or moderate agitation in patients suffering from schizophrenia or bipolar I disorder. Patients prefer this non-invasive treatment option to an injection.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
